Global Insomnia Market Size, Share, Forecast Report, 2020-2027

Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as it’s alone or conjugated with other psychiatric problems. Insomnia is most common is women and the severity may increase in conditions like pregnancy, postpartum, and menopause. The exact cause of insomnia is still a mystery. Many research has shown that biological, behavioural and psychological factors are responsible for initiating of insomnia. Different types of treatment are available in the market- Pharmacological and non-pharmacological treatment. Global Insomnia market is driving due to increase in the number of insomnia patient across the globe, technological advances and many other. While lack of education and awareness is the major restraining factor for the growth of market.
Key Players for Global Insomnia market

Eisai, Co. (Japan), Pfizer, Inc. (US), Merck & Co Inc (US), Sanofi (France), Takeda Pharmaceutical Company (Japan), Meda Consumer Healthcare Inc (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Flynn Pharma (UK), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), SkyePharma (UK), and Vanda Pharmaceuticals Inc. (US).
Segmentation
Global Insomnia Market has been segmented on the basis of types of therapy which comprises Pharmacological therapy which is further sub segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non Pharmacological therapy which is sub segmented into Relaxation therapy, Cognitive Behavioral Therapy, Sleep Hygiene Education, Stimulus Control, Paradoxical Intention and Other. By drug formulation they are segmented as Capsules, Tablet and others. On the basis of condition of diseases they are poor quality of sleep, sleep maintenance and other.